GINA recommendations in adults with symptomatic mild asthma and a smoking history
- PMID: 32029649
- DOI: 10.1183/13993003.00068-2020
GINA recommendations in adults with symptomatic mild asthma and a smoking history
Conflict of interest statement
Conflict of interest: H.K. Reddel reports research grants and personal fees for data monitoring committee work, consultancy, advisory board work and providing education from AstraZeneca, research grants, personal fees for data monitoring committee work, consultancy, advisory board work and providing education and non-financial support (study medication) from GlaxoSmithKline, personal fees for data monitoring committee work from Merck, research grants and personal fees for data monitoring committee work, advisory board work and providing education from Novartis, personal fees for providing education from Teva and Mundipharma, personal fees for advisory board work and providing education from Boehringer Ingelheim, personal fees for advisory board work from Sanofi Genzyme, outside the submitted work; and is Chair of the GINA Science Committee.
Comment on
-
GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents.Eur Respir J. 2019 Jun 27;53(6):1901046. doi: 10.1183/13993003.01046-2019. Print 2019 Jun. Eur Respir J. 2019. PMID: 31249014 No abstract available.
-
GINA recommendations in adults with symptomatic mild asthma and a smoking history.Eur Respir J. 2020 Feb 6;55(2):1902043. doi: 10.1183/13993003.02043-2019. Print 2020 Feb. Eur Respir J. 2020. PMID: 32029644 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical